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Abstract: 
Intestinal homeostasis is maintained through the interplay of the intestinal mucosa, local 
and systemic immune factors, and the microbial content of the gut. The cellular processes 
of autophagy, endoplasmic reticulum stress, the unfolded protein response and regulation 
of reactive oxygen species production are required to maintain a balance between pro-
inflammatory responses against potential pathogens and a tolerogenic response towards 
commensal bacteria. Intestinally active cytokines regulate innate immune pathways and 
cellular pathways within the gut mucosa. Disruption of these processes, or alterations in 
the cytokine milieu, can result in an improper response to the commensal gut microbial 
community leading to inappropriate inflammation characteristic of conditions such as 
inflammatory bowel disease. 
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 1. Introduction 
 
The gut represents a unique environment with an immense surface area specialized for 
nutrient and water absorption. The gut epithelium has among the highest mitotic rates in 
the body and epithelial cells undergo a constant cycle of maturation, apoptosis and 
renewal, all while maintaining exquisitely controlled barrier function [1]. The close 
proximity with the dense gut microbial community, which may harbor potential 
pathogens, requires precise adaptive and innate immunologic responses with a fine 
balance between tolerance and immune activation. This review will discuss intestinal 
homeostasis with a focus on intrinsic and innate immune pathways including barrier 
function, autophagy, endoplasmic reticulum stress and reactive oxygen species 
production, and their regulation by intestinally active cytokines. 
 
2 Barrier Function 
 
The primary role of the gut mucosa is selective absorption through transcytosis while 
preserving barrier function and maintaining intestinal homeostasis [2]. The maintenance 
of barrier function requires the dynamic regulation of multiple tissue and cellular 
structures and functions as summarised in Figure 1. The intestinal mucosal surface is 
comprised of a physical outer barrier of intestinal epithelial cells (IECs) joined by tight 
junctions and arranged into pore-like crypts, and in the small intestine protruding villi, 
protected by a layer of protective mucus which harbors a variety of secreted factors [3, 
4]. The epithelium is comprised of a monolayer of specialized intestinal epithelial cell 
types that perform distinct functions including absorptive enterocytes, hormone-secreting 
enteroendocrine cells, mucin-producing goblet cells, and anti-microbial peptide-
producing Paneth cells. Intestinal stem cells located at the base of each crypt provide a 
continual source of cell replenishment [5]. 
 
IECs actively maintain intercellular cohesion through tight junctions and desmosomes, 
which are carefully regulated to prevent diffusion of potential toxic substances or 
invasion by microbes. Tight junctions (TJ) are multi-protein complexes that regulate 
paracellular trafficking of macromolecules by engaging in selective permeability [2]. TJ 
are composed of four transmembrane proteins; occludin, claudin, junctional adhesion 
molecule, and tricellulin, that form a selective barrier by interactions with the adjacent 
cells [2, 3]. TJ are also composed of cytosolic scaffold proteins including zonula 
occludens proteins, which provide the foundation to the actin cytoskeleton by anchoring 
the transmembrane proteins [6]. Wounding of the mucosa and disruption of the 
intercellular connections, for example by chemically induced injury or infection, leads to 
rapid migration of epithelial cells into the denuded area and re-establishment of epithelial 
integrity [7, 8]. Structural abnormalities or functional perturbations in TJ can compromise 
the barrier function of the gut and significantly disturb homeostasis leading to intestinal 
disorders including inflammatory bowel disease (IBD), a condition characterized by 
chronic relapsing-remitting inflammation of the digestive tract. The resulting increase in 
permeability leads to internalization of TJ structural proteins (occludin, claudins, and 
junction adhesion molecule) further contributing to the inflammatory state [2]. Patients 
with IBD have reduced expression of occludin and junctional adhesion molecule-A, but 
cell culture models show a significant increase of claudin-2 [2, 9, 10]. While undetectable 
in normal colon, claudin-2 is strongly expressed along the inflamed crypt epithelium, and 
is correlated to increased TJ permeability [9]. Pro-inflammatory cytokines upregulated in 
IBD, including IL-6, induce the expression of claudin-2 correlating with increased rates 
of cell division in crypts, a feature characteristic of IBD [9, 11]. Thus the inflammatory 
state, and particularly the increase in pro-inflammatory cytokines, is characterized by 
increased paracellular permeability related to alterations in TJ structure and function. 
 
The mucous layer lies atop the epithelial cell layer and plays a critical role in host defense 
by providing a physical barrier, as well as additional protective mechanisms. The colonic 
mucous layer in particular plays an important role in separating the numerically abundant 
luminal bacteria from the epithelial surface [12]. Studies using fluorescence in situ 
hybridization to visualize bacteria residing in the gut lumen define a 50-micron bacterial-
free region above the mucosa termed the bacterial zone of exclusion, a firmly organized 
physical barrier impeding bacterial access to the epithelial surface [13]. The thick matrix 
of mucous is produced by intestinal goblet cells through the synthesis and secretion of 
mucin proteins. Mucins are large highly glycosylated glycoproteins which form a mesh-
like gel and are the main constituents of mucous [14, 15]. MUC2 is the most abundant 
mucin in intestinal mucous and is crucial to the mucous integrity and function [14]. Mice 
containing a missense mutation in the MUC2 gene, resulting in aberrant MUC2 assembly 
and a diminished mucus barrier, develop spontaneous distal colitis as well as enhanced 
susceptibility to chemical induced colitis. Moreover MUC2 mutant mice show evidence 
of increased endoplasmic reticulum (ER) stress in goblet cells, leading to up-regulation of 
the unfolded protein response (UPR) and dysregulated expression of genes involved in 
innate defense [16].  
 
The protective mucosal layer shields contact between gut bacteria and IECs, however 
emulsifiers, detergent-like agents commonly used in processed foods, can increase 
bacterial translocation across the epithelium and can cause IBD-like inflammation in 
mouse models. Emulsifiers commonly found in processed foods promote colitis in 
genetically predisposed mice, and induce low-grade inflammation in wild-type mice, 
highlighting the necessity of a fully operative mucosal barrier against disease 
development [17]. 
 
Murine models and human studies have revealed the importance of Paneth cells in 
protection from intestinal pathogens and influencing the relative abundance of 
commensal bacteria. Paneth cells are specialized secretory cells of the small intestinal 
epithelium that reside in small clusters at the base of crypts [18]. Their diverse secretory 
activity, which includes anti-microbial proteins, is strongly implicated in intestinal innate 
immunity [19]. Their unique ultrastructural characteristics, including extensive rough 
endoplasmic reticulum and Golgi complexes, facilitates Paneth cell secretory function 
and distinctly identifies the cell type [18]. Paneth cells contain large secretory granules 
rich in anti-microbial peptides, including α-defensins, lysozyme, lipopolysaccharide 
(LPS)-binding protein, and RegIII-γ, that are secreted into the mucous layer in response 
to exposure to microbes, or their products, and the pro-inflammatory cytokines TNF-α 
and IL1-β [18-20]. Secreted anti-microbial peptides and B-cell derived secretory 
immunoglobulin A (SIgA) in the mucous layer act as physicochemical shield impairing 
pathogenic bacteria from penetrating the mucous lining. Anti-microbial molecules bind 
with high affinity to enteric pathogens, however have low affinity for commensal 
bacteria, promoting a homeostatic microbial ecology through innate defense [12]. 
 
Defects in Paneth cell physiology or secretory activity can lead to increased inflammation 
by inducing ER stress, the UPR, apoptosis and autophagy (discussed below). These 
alterations may increase susceptibility to infection and predispose individuals to chronic 
inflammatory conditions including Crohn’s disease (CD), a form of IBD [20, 21].  
Reduced Paneth cell expression of the anti-microbial α-defensins HD5 and HD6 has been 
linked to ileal CD. In mice reduced expression of HD5 leads to a pronounced alteration of 
the luminal microbiota comparable to the deficiency of PC α-defensins in ileal CD [22]. 
Another link between Paneth cell dysfunction and CD is the innate immune receptor and 
susceptibility gene for CD called the nucleotide-binding oligomerisation domain–
containing protein 2 or NOD2 (discussed further below), which is highly expressed in 
Paneth cells. Murine models of NOD2‐deficient Paneth cells demonstrate reduced α‐
defensin expression when compared to the wild‐type mice [18]. NOD2‐deficient mice 
also show dysbiosis of commensal microbiota in the small intestine [23]. Reduced anti-
bacterial activity and decreased defensin production by Paneth cells may therefore 
contribute to the pathogenesis of CD [22]. 
 
3.1 Autophagy Overview 
 
Autophagy is a highly conserved catabolic process in eukaryotes required for the 
maintenance of cellular and tissue homeostasis [24]. It was initially characterized as a 
pathway required for starvation survival in yeast, but autophagy has since been 
recognized to be critical for fundamental processes including programmed cell death, 
proliferation, as well as cell mediated and innate immunity [25]. Autophagy involves the 
coordinated action of over 30 autophagy-related (ATG) proteins resulting in the 
characteristic formation of a double-membrane vesicle (autophagosome) engulfing 
targeted intracellular cargo. Autophagosomes are trafficked to and fuse with lysosomes to 
form an autolysosome resulting in subsequent degradation of cargo and liberation of 
amino acids from digested proteins [26]. This catabolic process liberates energy from 
degraded cargo including aged or damaged organelles and protein aggregates, thereby 
promoting cellular homeostasis [24]. Autophagy is required for maintaining intestinal cell 
survival and a normal colonic mucosa, as well as regulating inflammatory responses. 
Defects in autophagy-related genes are associated with inflammatory diseases of the 
gastrointestinal tract detailed below [27, 28].  
 
3.2 Autophagy and Intestinal immunity 
 
Studies have revealed the critical interplay that exists between autophagy and both innate 
and adaptive immunity. Autophagy has been implicated in the restriction of cytoplasmic 
bacterial replication, including Salmonella and adherent invasive E. coli, within epithelial 
cells [29, 30]. Autophagy is also involved in the secretion of pro-inflammatory cytokines 
by epithelial cells in response to bacteria. In macrophages and dendritic cells, autophagy 
negatively regulates the secretion of interleukin-1β (IL-1β) and IL-18, and disruption of 
autophagic pathways is linked to the increased release of IL-1β [31]. Autophagy is also 
involved in the processing and secretion of IL-1β through the non-canonical secretion 
pathway. Unconventional release of IL-1β is dependent on autophagy machinery and 
enhanced upon autophagy activation [32]. IL-1β is translocated into the lumen small 
vesicles which then acquires autophagosome markers with IL-1β accumulating in the 
space between the outer and inner membranes of the autophagosome, and is later secreted 
when autophagy is triggered [32]. Therefore autophagy appears to have opposing roles, 
restricting IL- β production through the conventional pathway, but facilitating its release 
through the unconventional pathway. 
 
In gut resident phagocytic cells, including macrophages and dendritic cells, autophagy is 
utilized for antigen presentation [33]. In the setting of macrophage infection by Listeria 
monocytogenes and Mycobacterium tuberculosis, autophagy is required to control 
infection [34]. This involves both recognition of the bacteria by adaptor proteins and 
killing within autophagolysosomes [35]. Autophagy intersects with innate immune 
pathways downstream of Toll-like receptor (TLR) interaction [36, 37]. Engagement of 
TLRs and NOD-like receptors by their ligands is a strong inducer of autophagy and 
downstream immune defense pathways [31, 36]. Within gastrointestinal macrophages, 
autophagy induced by TLR activation enhances pathogen degradation [37]. The 
engagement of TLR1, TLR3, TLR5, TLR6, and TLR7 leads to autophagy induction in 
macrophages [37]. Complementary data shows that knockdown of the autophagy protein 
Atg7 attenuates TLR-mediated IL-8 production in intestinal epithelial cells [38]. 
 
Pro-inflammatory cytokines and chemokines including IFN-γ, TNF-α, IL-1α, IL-2, and 
IL-6 have been shown to increase autophagy flux in macrophages [31, 37], while IL-4, 
IL-13, and IL-10 are inhibitory [39]. Autophagy can also have a direct influence on the 
production and secretion of cytokines including IL-1 β, IL-18, TNF-α, and Type I 
interferon [31]. This reciprocal relationship highlights the interdependence of autophagy 
and immune mediators. Autophagy is also required for B and T-cell survival and 
proliferation, and mice deficient in ATG5 have reduced numbers of B- and T-
lymphocytes. In addition, apoptosis in CD8+ T lymphocytes is dramatically increased in 
the absence of Atg5 [40]. Autophagy is also required for efficient functioning of antigen 
cross presentation by delivering endogenous antigens to class II major histocompatibility 
complex loading compartments for presentation to CD4+ T cells [41]. The requirement of 
autophagy for survival in immune cells and the prominent interactions between 
autophagy and cytokine production and response reveal its pivotal role in coordinating 
innate and adaptive immune responses.  
 
3.3 Autophagy in Intestinal Inflammation 
 
Autophagy facilitates multiple critical cellular functions and therefore alterations in this 
pathway can lead to pleomorphic effects including disruption of intestinal homeostasis as 
summarised in Figure 1. Large genome wide association studies have identified a coding 
polymorphism in the core autophagy gene ATG16L1 as a susceptibility gene for Crohn’s 
disease (CD) [33, 42-44]. The ATG16L1 risk polymorphism results in the substitution of 
an alanine for threonine, ATG16L1T300A, and leads to a modest increase in risk of 
developing CD. ATG16L1 is part of an enzymatic complex including Atg5 and Atg12 
that is required for the formation of autophagolysomes in mammalian cells. In addition to 
its role in cellular homeostasis, autophagy plays an important role in cellular defense 
against gastrointestinal invasive bacteria such as Salmonella, Shigella, Listeria and E. coli 
[29, 45-47]. Defects in ATG16L1 are associated with inefficient anti-bacterial autophagy 
[42, 48], contributing to the pathogenesis of CD. Anti-bacterial autophagy requires 
bacteria to be tagged for degradation, often through the conjugation of ubiquitin by the 
E3 ligase LRSAM1, resulting in recruitment of the autophagy machinery via the adaptor 
proteins NDP52 and p62/SQSTM1 [49-51]. Additional proteins have been implicated in 
the recruitment of autophagy machinery to invading bacteria including Nod2, which is 
recruited to sites of bacterial entry [52]. Recognition of cytoplasmic bacteria can be 
mediated through direct recognition by E3 ligases, or by membrane damage associated 
with bacterial invasion by galectin 8 [53]. Bacteria engulfed by autophagosomes are 
trafficked to the lysosome resulting in degradation of invasive bacteria.  
 
The Crohn’s disease risk polymorphism in ATG16L1 is associated with altered granule 
morphology and secretions in Paneth cells, even in the absence of Crohn’s disease [42]. 
Paneth cells are located at the base of intestinal crypts where they produce anti-microbial 
peptides and support the intestinal stem cell niche [42]. Using mice hypomorphic for 
ATG16L1 Cadwell et al found significant abnormalities in Paneth cells, including 
irregular, disorganized granules, reduced granule numbers, and decreased secretion of 
anti-microbial peptides similar to that observed in patients with CD [54]. Additionally, 
ATG16L1 deficiency in Paneth cells led to mitochondria degeneration and absence of 
apical microvilli. Nod2 activation in Paneth cells leads to defensin secretion and has also 
been linked to autophagy activation [25, 52]. Notably, deletion of Atg5 in the intestinal 
epithelium also showed Paneth cell and granule abnormalities, while other IECs appeared 
to be normal [42]. Additionally, loss of Atg7 and Atg4B produces similar defects as 
ATG16L1 hypomorphic mice, leading to Paneth cell abnormalities, once again 
highlighting this cell type’s sensitivity to autophagy disruption [55, 56]. 
 
The ATG16L1T300A polymorphism is associated with impaired anti-bacterial autophagy 
in vitro [29, 48]. Recently two independent groups reported on the in vivo effect using 
knock-in mice expressing the Atg16L1 T300A variant [44, 57]. The studies revealed 
abnormal Paneth cell lysozyme distribution, similar to patients with the CD T300A 
polymorphism and ATG16L1 hypomorphic mice. Furthermore CD11b+ cells isolated 
from the lamina propria exhibited impaired anti-bacterial autophagy and increased 
production of the pro-inflammatory cytokine IL-1β. Epithelial cells expressing Atg16L1 
T300A showed enhanced bacterial replication compared to wild-type cells. The observed 
effects were associated with an increased propensity of the T300A variant to be degraded 
by caspase-3 [44, 57]. Thus, caspase-3 activation in the setting of metabolic stress or 
infection causes a reduction in the level of the variant ATG16L1 leading to an increase in 
pro-inflammatory signaling and decreased bacterial clearance resulting in further 
increased inflammation. 
 
3.4 Pattern recognition receptors: Critical Inducers of Autophagy 
 
Pattern recognition receptors are inducers of autophagy and dysfunction of these 
detection systems can lead to widespread inflammation, believed to contribute to the 
exuberant immune response observed in CD [43]. Traditional genetic linkage and 
positional cloning strategies, as well as genome wide association studies, have identified 
loss-of-function mutations and polymorphisms in NOD2 as enhancing the susceptibility 
for the development of CD [24, 58]. Polymorphisms in both the ATG16L1 and NOD2 
genes are linked to Paneth cell dysfunction [52]. Mutations in NOD2 are linked to 
abnormalities in immune function that includes an overexpression of pro-inflammatory 
cytokines, and decreased expression of IL-10. Murine models of NOD2 deficiency lead 
to exaggerated intestinal inflammation as a result of this dysfunctional immune response 
[43]. NOD2 physically interacts with ATG16L1 and recruits the autophagy machinery to 
the site of bacterial entry into cells [52]. A physical interaction between the two proteins 
is necessary for autophagy-mediated clearance of pathogens [43]. Patients possessing 
mutations in both NOD2 and ATG16L1 have dysfunctional autophagy and impaired 
formation of autophagosomes [43]. Similarly to NOD2, NOD1 also contributes to 
ATG16L1 recruitment [52]. In addition, independently of its role in autophagy, 
ATG16L1 negatively regulates NOD1 and NOD2, leading to suppressed pro-
inflammatory downstream signaling [21]. 
 
Engagement of TLR2, TLR4 and TLR5 by their respective ligands stimulate autophagic 
clearance of pathogens in macrophages [59]. Furthermore, TLR4 stimulation by LPS 
results in an overexpression of pro-inflammatory cytokines IL-1β and IL-18 in 
ATG16L1-deficient macrophages compared to wild-type macrophages. Additionally, 
chimeric mice lacking Atg16L1 in the haematopoetic compartment are highly susceptible 
to chemically-induced colitis [59]. The elevated immune response in the context of 
Atg16L1 deficiency highlights the important interactions between autophagy and TLR-
mediated inflammatory response. 
 
3.5 Autophagy and ER stress 
 
The endoplasmic reticulum (ER) is responsible for the proper folding of secretory and 
membrane proteins. Intestinal cells are specialized for the secretion of proteins into the 
intestinal lumen and therefore are reliant on ER homeostasis, which can be easily 
disturbed by physiological and pathological conditions such as oxidative stress or energy 
deficiencies [60]. This leads to an accumulation of misfolded proteins, a condition known 
as ER stress, which is associated with inflammatory diseases, such as IBD and type-2 
diabetes. ER stress activates the unfolded protein response (UPR) [61], which plays a 
critical role in restoring ER homeostasis following accumulation of potentially toxic 
misfolded proteins [62]. 
 
Increased ER stress/UPR leads to induction of autophagy [62, 63]. The UPR leads to 
activation of three ER-resident transmembrane proteins: activating transcription factor 
6α, pancreatic ER eIF2α kinase (PERK) and inositol-requiring kinase 1α (IRE1α). The 
PERK–IRE1α pathway is essential for autophagy induction after ER stress [62]. 
Furthermore, gut inflammation induces the UPR in IECs leading to activation of the 
transcription factor X-box binding protein-1 (Xbp1) [62]. Deletion of Xbp1 within IECs 
results in excessive ER stress, Paneth cell apoptosis, spontaneous enteritis and increased 
secretion of pro-inflammatory cytokines including tumour-necrosis factor (TNFα) [38]. 
Selective deletion of Xbp1 in Paneth cells results in ER stress, autophagy induction and 
spontaneous ileitis [63]. Atg16l1/Xbp1 deficient mice, which lack UPR-induced 
autophagy in IECs, developed severe spontaneous CD-like ileitis as a result of IEC death, 
IRE1𝛼 -regulated NF-κB activation and TNF signaling [63]. This model reveals the 
important role of ATG16L1 in suppressing ER stress-induced inflammation, acting as a 
feedback mechanism by restraining IRE1α, modulating the pathologic overproduction of 
NF-κB, and preventing IEC death [63].  
 
Autophagy is also linked to ER stress through the NOD-like receptor family [61]. In 
addition to initiating anti-bacterial autophagy, NOD1 and NOD2 mediate ER-stress-
induced inflammation in IECs [61]. In murine models ER stress triggers the production of 
pro-inflammatory cytokine IL-6, which is dependent on NOD1 and NOD2 [61]. These 
findings suggest that variants in NOD2 may contribute to inflammatory conditions such 
as CD, not only through impairment of NOD-mediated inflammatory responses, but also 
through ER stress-induced autophagy.  
 
3.6 Autophagy and ROS 
 
Reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, play a role in 
regulating autophagy. ROS are generated in the mitochondria through nicotinamide 
adenine dinucleotide phosphate oxidases, and are involved in a variety of critical 
physiological and pathological processes associated with cell survival, death, and 
immune defenses [64]. Cell starvation induces the production of ROS, which can cause 
oxidative damage and cell death [65]. However ROS production can also promote cell 
survival through autophagy-mediated engulfment of damaged mitochondria [66]. In 
addition to activating starvation-induced autophagy, ROS can also activate anti-bacterial 
autophagy, and autophagic cell death, while autophagy can play a regulatory role by 
suppressing ROS production [65]. Along the intestinal epithelium, ROS produced in 
response to bacteria or pathogens play important roles in IEC signaling to promote 
epithelial repair and wound healing [67]. 
4.1 Cytokines: Modulators of Mucosal Homeostasis 
Cytokines play a key role in the maintenance of intestinal homeostasis, orchestrating the 
actions of innate and adaptive immunity imperative to host defense and healing through 
their pro- or anti-inflammatory actions. In the context of mucosal immunity cytokines 
regulate mucosal barrier function, influence immune cell migration and activation, and 
impact cellular metabolism to maintain a homeostatic environment. Cytokine 
dysregulation underlies the pathogenesis of multiple inflammatory disorders including 
Coeliac disease, eosinophilic disorders, ulcerative colitis and Crohn’s disease. The main 
sources of cytokines in the intestine include transient and resident lymphocytes, 
mononuclear cells - including macrophages and dendritic cells, polymorphonuclear cells, 
innate lymphoid cells as well as intestinal epithelial cells and supporting stromal cells.  
4.2 IL-1 – driver of inflammation 
 
The IL-1 family of pro-inflammatory cytokines plays a pivotal role in regulating mucosal 
immunity, particularly in the context of intestinal pathogens. Some members of the IL-1 
cytokine family are synthesized as pre-cursor proteins and secreted as mature proteins 
under inflammatory conditions via caspase-1-mediated cleavage (see Section 3.2) [68]. 
The IL-1 family is expressed throughout the GI tract where it has been associated with 
autoimmune and chronic inflammatory diseases [68, 69]. The IL-1 family of cytokines 
are predominately produced by stimulated macrophages, monocytes, fibroblasts, and 
dendritic cells, but can also be produced by lymphocytes and epithelial cells [70, 71]. In 
the gut, various family members including IL‐ 1α, IL‐ 1β, IL-18, IL-33 and IL-37 are 
produced directly by IECs [72]. IL‐ 1α and IL‐ 1β bind to two IL-1 receptor types; IL-1 
receptor type I and IL-1 receptor type II [71, 73]. Signaling is regulated by the IL-1 
receptor antagonist (IL- 1Ra), which competitively binds the IL-1RI. IL‐1α and IL‐1β 
are predominantly expressed by macrophages in inflamed tissue, whereas IL- 1Ra is 
produced mainly by IECs [73]. The balance of IL-1 and IL-1Ra secretion within the 
intestinal mucosa regulates the balance between inflammation and tolerance [74]. Early 
administration of IL-1Ra in murine models of colitis is associated with decreased tissue 
injury and reduced inflammation [75].  
 
Upon binding, IL-1RI initiates signal transduction promoting cell proliferation, while IL-
1RII acts as a natural inhibitor of IL-1 [73]. Although IL‐ 1α and IL‐ 1β signal through 
the same receptor complex, they have different activities and roles in inflammatory 
responses, including the pathogenic inflammation observed in ulcerative colitis [75]. 
IL‐ 1α acts as a regulatory cytokine, inducing the activation of transcription factors 
during times of cellular stress or inflammatory conditions promoting the expression of 
genes involved in cell proliferation and differentiation. IL-1α functions locally in the 
early stages of the immune response, and induces inflammation through the recruitment 
of neutrophils. In contrast, IL‐ 1β acts systemically and is involved in mediating 
widespread inflammatory responses that may eventuate tissue damage [73, 75]. IL-1β 
expression is significantly enhanced in the inflamed mucosa of patients with IBD 
compared with healthy patients [76].  
 
Full length IL-1α is able to facilitate pro-inflammatory gene transcription independent of 
IL-1R1 binding [77]. IL-1α contains a nuclear localisation sequence within the N-
terminal portion of the molecule. Unlike IL-1β, IL-1α can act as a damage-associated 
molecular pattern (DAMP); molecules or alarmins released by stressed cells undergoing 
necrosis that function as endogenous signals of danger by activating immune responses. 
Binding rapidly initiates the production of chemokines and inflammatory cytokines, 
promoting ‘sterile inflammation’ in the absence of infection [78].  
 
IL-1α and IL-1β may have further implications in intestinal inflammation through 
autophagy (see Section 3.2). Induction of autophagy is associated with decreased IL-1α 
and IL-1β production, and disruption of autophagic flux leads to increased secretion. 
Working in a negative feedback fashion, the two cytokines exhibit regulatory roles by 
inducing autophagosome formation [39]. 
 
Other members of the IL-1 family have pronounced roles in regulating intestinal 
inflammation. IL-33 is upregulated within inflamed mucosa in patients with IBD and is 
associated with delayed wound healing and impaired epithelial barrier function in 
chemically-induced colitis models. IL-33-deficient mice have reduced intestinal 
inflammation compared to controls, reinforcing its pro-inflammatory function in the 
colon [79]. Interesting, recent evidence may suggest a protective role of IL-33 in mucosal 
immunity against parasites. By promoting the expansion of innate effector leukocytes, 
called nuocytes, IL-33 facilitates an effective immune response that leads to epithelial 
and goblet cell proliferation and eosinophilic infiltration in the gut mucosa [80]. Notably 
the activity of pro-inflammatory IL-18 has been implicated in several autoimmune 
diseases including IBD [81]. Throughout the GI tract, IL-18 is produced primarily by 
macrophages and DCs. IL-18 mediates its immunoregulatory role by inducing pro-
inflammatory IFNγ release from natural killer cells [81, 82]. IL-18 deficient mice have 
reduced mucosal inflammation in murine models of CD [83]. Neutralization with the IL-
18 antibody leads to a decrease in IFNγ, and reduction of IFNγ in CD is associated with a 
protective clinical response [82]. Finally, blocking IL-18 with the IL-18 binding protein 
reduces experimental colitis [81]. These studies highlight the contribution of IL-1 family 
members in initiating and regulating gut inflammation. 
 
4.3 IL-10 – regulator of inflammation 
The IL-10 family of cytokines comprises nine members including the IL-20 subfamily 
and the type III IFN family [74]. IL-10 itself is a critical anti-inflammatory cytokine in 
the regulation of mucosal homeostasis [84]. Binding of IL-10 to its heterodimeric 
transmembrane receptor complex consisting of IL-10R1 and IL-10R, results in the 
activation of the Jak/STAT signaling pathway and subsequent activation of the 
transcriptional factors STAT3 and STAT1, and in non-macrophage cells STAT5 [85]. 
Intestinal sources of IL-10 include T cells, B cells, and activated monocytes [74, 84]. IL-
10 attenuates chronic intestinal inflammation by potently inhibiting antigen presentation 
and the subsequent release of pro-inflammatory cytokines such as IL-1α, IL-1β, TNFα, 
IFN-γ, and IL-6 [69, 86]. IL-10 dampens acute inflammation caused by activated 
macrophages and dendritic cells (DC) in response to pathogen detection [87]. IL-10 also 
limits the proliferation and differentiation of T cells by inhibiting antigen-presentation on 
antigen presenting cells and down regulating class II major histocompatibility complex 
(MHC) expression [88]. 
 
Several lines of evidence support a protective role for IL-10 signaling in limiting the 
pathogenesis of IBD. Genome-wide association studies show that polymorphisms in the 
IL-10 gene are associated with an increased risk for IBD [89-91]. Additionally, studies 
show that patients with homozygous loss of function mutations in IL-10 and IL10R 
develop a severe form of IBD with a very early onset (under the age of 5) [92]. 
 In the gut, IL-10 is primarily produced by a subset of CD4+ T cells known as regulatory 
T (Treg) cells. Treg cells suppress inflammatory responses that may cause tissue damage 
by producing IL-10 and other anti-inflammatory cytokines [93]. Depletion of Treg cells 
or disruption of IL10 or its receptor results in spontaneous colitis [94]. T cell-specific IL-
10R signaling is important for suppression of inflammation, however IL-10 detection by 
innate immune cells is also required for regulating intestinal inflammation and preventing 
colitis, independent of its effects on T cells. In mice, IL-10R-disruption on CD4+ T cells 
impairs Treg cell differentiation and function and leads to the development severe colitis. 
The loss of IL-10R signaling also results in the impaired generation of intestinal 
macrophages and their ability to secrete IL-10. Importantly, IL-10R-dependent signals 
determine the functional fate of intestinal macrophages as predominantly pro-
inflammatory or anti-inflammatory [89].  
 
IL-10 has a critical role in the regulation of intestinal inflammation and maintenance of 
homeostasis. IL-10-deficient mice develop extensive intestinal inflammation and chronic 
enterocolitis reminiscent of human celiac disease and ulcerative colitis [95]. IL-10 
deficiency results in an accumulation of inflammatory infiltrates in the mucosa and 
defective expression of MHC class II molecules in IECs which leads to disease pathology 
[95]. IL-10-deficient mice in germ-free conditions do not develop colitis or immune 
system activation, demonstrating that resident enteric bacteria are necessary for the 
development of spontaneous colitis and that IL-10 plays an important role in the 
generally tolerogenic immune response to commensal gut bacteria [96]. Interestingly, in 
macrophages it is the loss of IL-10R expression, and not the loss of gut resident 
macrophage IL-10 production, that leads to spontaneous development of severe colitis, 
emphasizing the importance of the innate immune response to this cytokine [97].  
 
IL-10 also exerts effects on the intestinal epithelial cells by driving mucin production in 
goblet cells and maintaining barrier function (see Section 2). Administration of antibodies 
against IL-10 or IL-10R leads to a rapid increase in ER stress and T-cell-mediated 
inflammation in mice harbouring a MUC2 point mutation that develop spontaneous 
colitis. IL-10 antibody administration enhances MUC2 misfolding in the ER of goblet 
cells, which leads to an accumulation of proteins and subsequent activation of the UPR 
[98]. This demonstrates the direct effect of IL-10 on modulating cellular homeostasis and 
consequently mucus production by goblet cells. 
 
Murine IECs deficient in IL-10 show altered interactions with non-pathogenic enteric 
bacteria resulting in chronic inflammation [99]. Wild type and IL-10-deficient germ-free 
mice colonized with non-pathogenic bacteria express a completely different set of 
regulatory proteins as determined by proteomic analysis. The changes in protein levels 
identify pathways responsible for regulating ER stress, energy metabolism, and apoptosis 
as contributing to the observed inflammation and loss of tissue homeostasis in the IL-10 
deficient mice [100]. The absence of colitis observed in wild-type mice reveals the 
tolerogenic role that IL- 10 plays in the interplay between commensal enteric bacteria and 
the intestinal mucosa [99, 100].  
 
IL-10 modulates immune responses in the intestine and is involved in regulation of ER 
stress, energy metabolism and apoptosis. Murine knockout models, as well as 
translational studies from patients harboring mutations, suggest that IL-10 and its 
receptor are key regulators of mucosal homeostasis.  
 
 
4.4 IL-22 and gut homeostasis 
 
Among the intestinally active cytokines, IL-22 plays a key role in regulating mucosal 
barrier function and maintaining intestinal homeostasis. This cytokine has both pro-
inflammatory and anti-inflammatory functions but studies suggest a protective role for 
IL-22 in the gut. IL-22 is member of the IL-10 cytokine family, and is produced by innate 
lymphoid cells, dendritic cells, neutrophils and various subtypes of CD4+ T cells, most 
notably; Th17, Th1 and Th22 cells [101, 102]. IL-22 is recognized by a heterodimeric 
receptor complex composed of two subunits, IL-10R2 which is expressed on a broad 
array of tissues and IL-22R1, which is expressed in a limited number of tissues including 
the intestine, lung and skin [103]. Therefore the effects of IL-22 are important to barrier 
surfaces including the mucosal epithelia of the digestive system [104]. IL-22R1 is highly 
expressed by epithelial cells of the small intestine under normal conditions but only 
expressed in the colonic epithelium under inflammatory conditions [105]. The binding of 
IL-22 to its receptor induces Jak-mediated STAT3 phosphorylation and subsequent 
nuclear translocation, resulting in transcriptional upregulation of various anti-microbial 
peptides and mucins. IL-22 signalling restores barrier function during inflammation and 
its protective role for the gut mucosa has also been demonstrated in mouse models of 
colitis. In the intestine, IL-22 promotes wound healing, tissue regeneration, and epithelial 
cell proliferation [106, 107]. It regulates epithelial-microbial homeostasis through the 
induction in IECs of anti-microbial peptides, specifically of the Reg family, including 
RegIIIβ and RegIIIγ, as well as β-Defensin 2 and β-Defensin 3 [103, 108]. Through the 
production of these AMPs, IL-22 significantly contributes to innate defense to maintain 
the epithelial integrity of the colon during colitis. 
 
IL-22 also plays an important role in alleviating oxidative stress, one of the key features 
of chronic inflammation [109]. IL-22 stimulation induces the transcription of proteins 
that protect from cellular stress [106]. As stated earlier, conditions of stress initiate the 
immune response and through the induction of specific proteins, IL-22 can counteract 
uncontrolled inflammation. In animal models, IL-22 is associated with susceptibility to 
colonic inflammation [110] and dysregulated IL-22 expression at barrier surfaces is 
associated with inflammatory human disease, suggesting a critical role in the 
maintenance of normal barrier homeostasis [106, 111].  An aggressive immune response 
is associated with an increase in pro-inflammatory cytokines that may impair epithelial 
TJs and lead to a diminished mucosal barrier. In mice with diet induced colonic 
inflammation, administration of IL-22 limits excessive inflammation by reducing both 
ER and oxidative stress, improving the integrity of the mucosal barrier [112].  
 
In vivo IL-22 gene delivery targeting inflamed tissue leads to the rapid amelioration of 
local intestinal inflammation in a STAT3 dependent manner [105, 106, 110]. Knockout 
mice with IEC-specific deletion of STAT3 activity are highly susceptible to experimental 
colitis [106]. Thus, activation of STAT3 pathways appears to be crucial for attaining the 
protective benefits of IL-22 against colitis. In the colon goblet cell depletion is a 
characteristic finding in IBD and IL-22 promotes goblet cell restitution, which correlates 
with STAT3 activation [110]. Heterologous expression of IL-22 in the colon results in 
improvement in chronic colitis through restoration of goblet cells and enhanced mucus 
production, thereby alleviating disease severity [110].  
 
Studies focusing on the protective role for IL-22 show that treatment with anti-IL-22 
antibody in the recovery phase of chemically-induced murine colitis results in impaired 
recovery. Antibody-mediated inactivation of IL-22 is associated with a thin colonic wall 
and reduced goblet cell restoration, as well as more severe weight-loss and extensive 
inflammation, demonstrating the importance of endogenous IL-22 in limiting 
inflammation and maintaining homeostasis [110]. Furthermore, ethanol and burn-induced 
mucosal injury results in increased intestinal permeability and decreased Reg3γ 
expression that is rescued by IL-22 administration [113]. These findings suggest that the 
IL-22 may have therapeutic potential by accelerating recovery following mucosal injury 
and restoring anti-microbial peptide pathway.  
 
IL-22 binds competitively to the secreted IL-22 binding protein (IL-22BP) also known as 
IL22RA2, with an affinity of 20- to 1,000-fold higher than the IL22 receptor [104]. 
Under basal conditions, IL-22BP is highly expressed by dendritic cells in the colon 
leading to low IL-22 activity, however under inflammatory conditions, and particularly 
during the recovery phase following chemical injury, IL-22BP is down regulated, 
promoting IL-22 mediated homeostatic effects [114, 115]. Heterologous overexpression 
of IL-22BP suppresses IL-22-mediaited goblet cell restitution during the of recovery 
phase of murine colitis [110]. Although the IL-22-IL-22BP axis remains incompletely 
understood, the findings to date support a crucial role for endogenous IL-22BP in 
regulating intestinal tissue repair, and additionally reveal the inverse pattern of effects of 
IL-22BP with IL-22.  
 
 
5 Conclusion 
 
The maintenance of intestinal homeostasis relies on the critical interactions of the innate 
and adaptive immune system acting on critical pathways within the gut mucosa. Barrier 
function within the epithelium is maintained through intercellular adhesion that limits 
access to the underlying lamina propria and circulatory system. In addition the mucous 
layer that is secreted by goblet cells contains secreted anti-microbial peptides and 
immunoglobulins that protect against potential pathogens. Innate cellular process 
important for maintaining homeostasis including autophagy, ER stress and ROS, and 
these processes are involved in bidirectional regulation with secreted cytokines and 
immune cells. Pro-inflammatory signalling, which is critical for host defense against 
pathogens, is balanced against anti-inflammatory pathways that promote tolerance to 
commensal gut flora. Disruption of this balance can lead to pathologic inflammatory 
conditions of the gut, including inflammatory bowel disease. 
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Figure Legends 
Figure 1. (A) Overview of the villus crypt architecture. (B) Perturbations underlying the 
loss of intestinal homeostasis in the setting of pathologic inflammation. (C) Normal crypt 
homeostasis. (D) Effect of impaired autophagy on crypt homeostasis. 
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